Name | XMD-17-51 Trifluoroacetate |
Description | XMD-17-51 Trifluoroacetate is a pyrimido-diazepinone compound that regulates protein kinases. |
In vitro | XMD-17-51 Trifluoroacetate is a pyrimido-diazepinone compound proficient in modulating an extensive range of protein kinases, such as MPS1 (TTK), ERK5 (BMK1, MAPK7), various polo kinases, Ack1, Ack2, Abl and its mutants, DCAMKL1, ABL1, DCAMKL2, and many others including Bcr-Abl, GAK, cSrc, and Trk family proteins. This versatility renders it applicable in treating a diverse array of diseases, disorders, or conditions [1]. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | Ethanol : 8 mg/ml (19.78 mM) H2O : 2 mg/ml (4.94 mM) DMSO : 80 mg/ml (197.78 mM)
|
Keywords | 1628614-50-5 | 1628614-50-5 free base | XMD 17 51 Trifluoroacetate | XMD1751 Trifluoroacetate | XMD-17-51 Trifluoroacetate |
Inhibitors Related | Phenformin hydrochloride | AICAR | Doxorubicin hydrochloride | Adenosine monophosphate | Metformin | Methyl cinnamate | A-769662 | Metformin hydrochloride | Chitosan oligosaccharide | Buformin hydrochloride | HTH-01-015 | AMPK activator 4 |
Related Compound Libraries | Bioactive Compound Library | Epigenetics Compound Library | Kinase Inhibitor Library | Anti-Cancer Metabolism Compound Library | Anti-Obesity Compound Library | Anti-Ovarian Cancer Compound Library | Inhibitor Library | Metabolism Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max |